Search
for
Sort by
Research 211–240 of 1000+
- MP44-04 TRENDS IN 5-ALPHA REDUCTASE INHIBITOR USE BEFORE AND AFTER THE FOOD AND DRUG ADMINISTRATION SAFETY WARNING
- Alpha Blocker and 5-Alpha Reductase Inhibitor Prescribing Habits among Urologists and Primary Care Physicians
- 705 Influence of 5a-Reductase Inhibitor (5-ARI) Usage on the Reproductive Function of Married Men
- MP85-05 SEXUAL DYSFUNCTION AFTER 5-ALPHA REDUCTASE INHIBITOR USE: INSIGHTS FROM THE REDUCE STUDY GROUP DATABASE
- 1153 ERECTILE HEMODYNAMICS ASSESSMENT IN MEN WITH PERSISTENT ERECTILE DYSFUNCTION AFTER 5-ALPHA REDUCTASE INHIBITOR USE
- Solubilization and Solid‐State Characterization of a Poorly Soluble 5‐α Reductase Inhibitor
- (719) Signal Detection of Depression and Suicidality With the 5-Alpha Reductase Inhibitors: Evidence from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) Database
- Impact of 5-alpha Reductase Inhibitors on Male Reproductive Health: A Review of Finasteride and Dutasteride.
- Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
- Supplementary Material for: Drug-Induced Melasma in Patients on 5-Alpha Reductase Inhibitors: A Case Report
- Supplementary Material for: Drug-Induced Melasma in Patients on 5-Alpha Reductase Inhibitors: A Case Report
- Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
- Depression risk of 5-alpha reductase inhibitors: A systematic review and meta-analysis with a focus on comparator groups
- An exploratory analysis of 5‐alpha reductase inhibitors and risk of opioid use disorder among male Medicare beneficiaries receiving prescription opioid medications
- Comparative Efficacy of Minoxidil and 5‐Alpha Reductase Inhibitors Monotherapy for Male Pattern Hair Loss: Network Meta‐Analysis Study of Current Empirical Evidence
- 5-Alpha Reductase Inhibitors on Hypersexuality During the Manic Phase of Bipolar and Psychotic Patients; New Insight to a Well-Known Medicines
- Risk associated with the use of 5-alpha reductase inhibitors with minoxidil in treatment of male androgenetic alopecia – literature review
- Risk of Estrogen-Driven Malignancies in Females on 5-alpha Reductase Inhibitors
- LB891 Analysis of breast health outcomes in women on oral 5-alpha reductase inhibitors: A single-center retrospective cohort study
- MP31-04 HOW DO 5-ALPHA-REDUCTASE INHIBITORS CHANGE PSA DENSITY IN PATIENTS ON ACTIVE SURVEILLANCE?
- Use of 5-Alpha Reductase Inhibitors in Dermatology: A Narrative Review
- The relative effect of monotherapy with 5‐alpha reductase inhibitors and minoxidil for female pattern hair loss: A network meta‐analysis study
- A proposed etiopathology of persistent dysfunctions emerging from use and discontinuation of 5-alpha reductase inhibitors: sequelae of drug-mediated microvasculopathy
- Correction to: An evaluation of the federal adverse events reporting system data on adverse effects of 5‑alpha reductase inhibitors
- 5 Alpha Reductase Inhibitors
- 5-alpha reductase inhibitors: New evidences on benefits and harms beyond benign prostatic hyperplasia
- What do we know about 5-alpha reductase inhibitors?
- HP-01-004 Histomorphometrical Evaluation of The Corpus Cavernosum of Hypertensive Rats Treated with 5-Alpha-Reductase Inhibitors
- MP09-16 5-ALPHA REDUCTASE INHIBITORS FOR MALE LOWER URINARY TRACT SYMPTOMS: A COCHRANE SYSTEMATIC REVIEW AND META-ANALYSIS
- Effect of 5α-reductase inhibitors on sexual function: New contributions